Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.
Frequently asked questions
What sector does Noile-Immune Biotech Inc (4893) operate in?
Noile-Immune Biotech Inc belongs to the Other sector and operates in the Biotechnology industry.
What is Noile-Immune Biotech Inc (4893) current stock price?
As of the latest data, Noile-Immune Biotech Inc stock price is ¥87, with a previous close of ¥89. Noile-Immune Biotech Inc lost -¥2 in the last trading session, representing a -2.25% loss.
What is Noile-Immune Biotech Inc (4893) current market capitalization?
Noile-Immune Biotech Inc market cap is approximately 3.78 billion.
What is Noile-Immune Biotech Inc (4893) Earnings Per Share (EPS)?
The trailing EPS is -¥17, and the forward EPS is -¥24.
What is Noile-Immune Biotech Inc (4893) EBITDA?
Noile-Immune Biotech Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -217.96 million.
Does Noile-Immune Biotech Inc (4893) pay dividends?
No. Noile-Immune Biotech Inc does not pay a dividend.
What is Noile-Immune Biotech Inc (4893) beta (volatility) score?
Noile-Immune Biotech Inc has a beta of 0.298, indicating lower volatility than the overall market.